Editas Medicine Inc. (NASDAQ:EDIT) shares saw unusually-strong trading volume on Thursday . Approximately 283,829 shares changed hands during mid-day trading, an increase of 31% from the previous session’s volume of 217,243 shares.The stock last traded at $18.00 and had previously closed at $19.06.

A number of analysts have recently weighed in on EDIT shares. Vetr upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 target price for the company in a research note on Monday, May 9th. Cowen and Company restated a “buy” rating on shares of Editas Medicine in a research note on Monday, May 16th. Zacks Investment Research lowered Editas Medicine from a “hold” rating to a “sell” rating in a research note on Wednesday, May 18th. Finally, Jefferies Group assumed coverage on Editas Medicine in a research note on Thursday, June 2nd. They issued a “hold” rating and a $35.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $33.50.

The stock’s market capitalization is $660.99 million. The company has a 50 day moving average price of $24.17 and a 200 day moving average price of $29.26.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). Equities research analysts anticipate that Editas Medicine Inc. will post ($2.59) EPS for the current year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.